165 related articles for article (PubMed ID: 11365845)
1. Immune based therapy update.
Proj Inf Perspect; 1998 Sep; (25):17-9. PubMed ID: 11365845
[TBL] [Abstract][Full Text] [Related]
2. IL-2 taken to HAART.
Gilden D
GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 immunogen (remune).
Newsline People AIDS Coalit N Y; 1998 Dec; ():36. PubMed ID: 11367099
[TBL] [Abstract][Full Text] [Related]
4. [Immune-based therapies and HIV infection].
Weiss L
Ann Med Interne (Paris); 2002 Jun; 153(4):227-36. PubMed ID: 12218888
[TBL] [Abstract][Full Text] [Related]
5. Two years of IL-2 in early HIV disease--fantastic increases in CD4+ cell counts.
TreatmentUpdate; 1999 Mar; 11(2):4-5. PubMed ID: 11366777
[TBL] [Abstract][Full Text] [Related]
6. Rebuilding the immune system.
Averitt D
WORLD; 1999 Apr; (No 96):1-2. PubMed ID: 11366944
[TBL] [Abstract][Full Text] [Related]
7. Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies.
Angel JB
AIDS Read; 2001 Apr; 11(4):209-21. PubMed ID: 11392678
[TBL] [Abstract][Full Text] [Related]
8. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s.
Valdez H; Mitsuyasu R; Landay A; Sevin AD; Chan ES; Spritzler J; Kalams SA; Pollard RB; Fahey J; Fox L; Namkung A; Estep S; Moss R; Sahner D; Lederman MM
J Infect Dis; 2003 Jan; 187(2):320-5. PubMed ID: 12552459
[TBL] [Abstract][Full Text] [Related]
10. Improved treatment results with interleukin-2.
HIV Hotline; 1998 May; 8(2):13-4. PubMed ID: 11365363
[TBL] [Abstract][Full Text] [Related]
11. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A
J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 (IL-2, Proleukin).
Proj Inf Perspect; 1999 Apr; (27):21-2. PubMed ID: 11366737
[TBL] [Abstract][Full Text] [Related]
13. HIV-specific immune responses restored by HIV immunogen plus antiretroviral suppression.
James JS
AIDS Treat News; 1998 Jul; (No 298):1-5. PubMed ID: 11365597
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 clinical trials.
Newsline People AIDS Coalit N Y; 1998 Sep; ():58. PubMed ID: 11367495
[TBL] [Abstract][Full Text] [Related]
15. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-7 (IL-7): immune function, involvement in the pathogenesis of HIV infection and therapeutic potential.
Beq S; Delfraissy JF; Theze J
Eur Cytokine Netw; 2004; 15(4):279-89. PubMed ID: 15627636
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
[TBL] [Abstract][Full Text] [Related]
18. Moods brighten as statistics lighten.
Gilden D
GMHC Treat Issues; 1998 Mar; 12(3):1-5. PubMed ID: 11365390
[TBL] [Abstract][Full Text] [Related]
19. A primer on HIV type 1-specific immune function and REMUNE.
Moss RB; Giermakowska WK; Savary JR; Theofan G; Daigle AE; Richieri SP; Jensen FC; Carlo DJ
AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S167-75. PubMed ID: 9672235
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC
J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
